SFT-002

SFT-002 is an investigational inhaled dry powder formulation being developed by invoX Pharma for the treatment of cystic fibrosis. The drug is delivered using the proprietary Softhaler® platform, a high-efficiency dry powder inhaler (DPI) technology designed to optimize drug deposition in the lungs. As of early 2024, SFT-002 is in the early stages of development (preclinical). While the specific active pharmaceutical ingredient and its molecular mechanism of action have not been publicly disclosed, the program is part of invoX's internal pipeline focusing on respiratory diseases including COPD, asthma, and pulmonary fibrosis.

Other names

SFT-002-IVOXSFT002-IVOXSFT 002-IVOX